Your browser doesn't support javascript.
loading
Safety and immunogenicity of SARS-CoV-2 self-amplifying RNA vaccine expressing an anchored RBD: A randomized, observer-blind phase 1 study.
Akahata, Wataru; Sekida, Takashi; Nogimori, Takuto; Ode, Hirotaka; Tamura, Tomokazu; Kono, Kaoru; Kazami, Yoko; Washizaki, Ayaka; Masuta, Yuji; Suzuki, Rigel; Matsuda, Kenta; Komori, Mai; Morey, Amber L; Ishimoto, Keiko; Nakata, Misako; Hasunuma, Tomoko; Fukuhara, Takasuke; Iwatani, Yasumasa; Yamamoto, Takuya; Smith, Jonathan F; Sato, Nobuaki.
Affiliation
  • Akahata W; VLP Therapeutics Japan, Inc., Marunouchi, Minato-ku, Tokyo 105-0003, Japan. Electronic address: wakahata@vlptherapeutics.com.
  • Sekida T; VLP Therapeutics Japan, Inc., Marunouchi, Minato-ku, Tokyo 105-0003, Japan.
  • Nogimori T; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 567-0085, Japan.
  • Ode H; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi 460-0001, Japan.
  • Tamura T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
  • Kono K; VLP Therapeutics Japan, Inc., Marunouchi, Minato-ku, Tokyo 105-0003, Japan.
  • Kazami Y; VLP Therapeutics Japan, Inc., Marunouchi, Minato-ku, Tokyo 105-0003, Japan.
  • Washizaki A; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 567-0085, Japan.
  • Masuta Y; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 567-0085, Japan.
  • Suzuki R; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan.
  • Matsuda K; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA.
  • Komori M; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA.
  • Morey AL; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA.
  • Ishimoto K; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA.
  • Nakata M; VLP Therapeutics Japan, Inc., Marunouchi, Minato-ku, Tokyo 105-0003, Japan.
  • Hasunuma T; Department of Research, Kitasato University, Kitasato Institute Hospital, Minato-ku, Tokyo 108-0072, Japan.
  • Fukuhara T; Department of Microbiology and Immunology, Faculty of Medicine, Hokkaido University, Sapporo, Hokkaido, Japan; Laboratory of Virus Control, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871, Japan.
  • Iwatani Y; Clinical Research Center, National Hospital Organization Nagoya Medical Center, Nagoya, Aichi 460-0001, Japan; Division of Basic Medicine, Nagoya University Graduate School of Medicine, Nagoya, Aichi 466-8550, Japan.
  • Yamamoto T; Laboratory of Precision Immunology, Center for Intractable Diseases and ImmunoGenomics, National Institutes of Biomedical Innovation, Health and Nutrition, Ibaraki, Osaka 567-0085, Japan.
  • Smith JF; VLP Therapeutics, Inc., Gaithersburg, MD 20878, USA.
  • Sato N; VLP Therapeutics Japan, Inc., Marunouchi, Minato-ku, Tokyo 105-0003, Japan.
Cell Rep Med ; 4(8): 101134, 2023 08 15.
Article in En | MEDLINE | ID: mdl-37586325
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Clinical_trials Limits: Humans / Middle aged Language: En Journal: Cell Rep Med Year: 2023 Type: Article
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Database: MEDLINE Main subject: Vaccines / COVID-19 Type of study: Clinical_trials Limits: Humans / Middle aged Language: En Journal: Cell Rep Med Year: 2023 Type: Article